Results 191 to 200 of about 15,380 (223)

FOLFIRINOX Adjuvant Therapy for Pancreatic Cancer

New England Journal of Medicine, 2019
Caterina Vivaldi, Lorenzo Fornaro
exaly   +4 more sources

Neoadjuvant FOLFIRINOX improves outcomes

Nature Reviews Clinical Oncology, 2018
exaly   +2 more sources

Continued adjuvant FOLFIRINOX for BRPC or LAPC after neoadjuvant FOLFIRINOX

Journal of Cancer Research and Clinical Oncology, 2022
We aimed to assess the role of adjuvant FOLFIRINOX, in comparison with other adjuvant therapy, in patients who received neoadjuvant FOLFIRINOX and surgery for borderline resectable or locally advanced pancreatic cancer (BRPC or LAPC).Our target population was patients with BRPC or LAPC, who received adjuvant therapy following neoadjuvant FOLFIRINOX and
Jaewoo Park, Hae Young Kim, Hee Young Na, Jun Suh Lee, Jong-Chan Lee, Jin Won Kim, Yoo-Seok Yoon, Jin-Hyeok Hwang, Ho-Seong Han, Jaihwan Kim   +9 more
openaire   +2 more sources

FOLFIRINOX as First-line Chemotherapy in Japanese Patients Suffering from Metastatic Pancreatic Cancer (KOBE FOLFIRINOX Study)

Cancer Diagnosis & Prognosis, 2022
Background/Aim: FOLFIRINOX (oxaliplatin, irinotecan, 5-fluorouracil, and leucovorin) combination chemotherapy is the gold-standard therapy for advanced pancreatic cancer. In this study, FOLFIRINOX dosages for Japanese patients were established enabling FOLFIRINOX therapy optimization for efficient use.
Yukimasa, Hatachi, Sharad R, Mohan, Takeshi, Kotake, Hironaga, Satake, Yoshihiro, Okita, Hisateru, Yasui, Akihito, Tsuji   +6 more
openaire   +2 more sources

FOLFIRINOX for advanced pancreatic cancer: The Princess Margaret experience.

Journal of Clinical Oncology, 2015
417 Background: The FOLFIRINOX regimen has been shown to significantly increase both overall (OS) and progression free (PFS) survival in metastatic pancreas cancer (MPC), albeit with an increase in adverse events (AEs). It is not known whether initial dose reductions compromise FOLFIRINOX efficacy and there are limited data regarding treatment of ...
Chllamma, Muralidharan, Cook, Natalie, Giby, Kazim, Dodd, Anna, Wang, Lisa, Dhani, Neesha C., Hedley, David W., Moore, Malcolm J.   +7 more
openaire   +2 more sources

Kuurschema folfirinox bij pancreastumor kan efficiënter

Pharmaceutisch Weekblad, 2022
Door een kritische blik te werpen op het kuurschema van FOLFIRINOX is de Werkgroep Duurzaamheid en Doelmatigheid van de Nederlandse Vereniging Voor Medische Oncologie (NVMO) erin geslaagd dit schema patiëntvriendelijker, tijdbesparend en kosteneffectiever te maken.
Lubberts, Esther, Van De Poll, Matthijs E.C., Wymenga, Machteld, Los, Maartje, Hendrikx, Jeroen J.M.A., Sonke, Gabe S., Willemsen, Annelieke E.C.A.B., Goosens, Anniek, Van Leeuwen, Roelof W.F.   +8 more
openaire   +1 more source

Leucovorin, Fluorouracil, Irinotecan, and Oxaliplatin (FOLFIRINOX) Regimen

Hospital Pharmacy, 2011
The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
J. Aubrey Waddell, Dominic A. Solimando
openaire   +1 more source

FOLFIRINOX: A Small Step or a Great Leap Forward?

Journal of Clinical Oncology, 2011
Clinical trials in advanced pancreatic cancer during the last couple of decades have almost uniformly yielded disappointing results. To date, the paradigm for almost all phase III studies has been to compare the long-time reference standard, gemcitabine, with a gemcitabinebased combination regimen.
openaire   +2 more sources

Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial

Lancet Oncology, The, 2021
Veronique Vendrely, Christophe Borg, Olivier Bouché   +2 more
exaly  

FOLFIRINOX: A Great Leap Forward, but for Whom?

Journal of Clinical Oncology, 2012
Lucas Vieira, dos Santos, Diocésio Pinto, de Andrade, João Paulo, Lima   +2 more
openaire   +2 more sources